What serious adverse reactions happened during this study?
The tables below show the serious adverse reactions that happened during the
study.
Serious adverse reactions related to MEDI5083
Part 1 Part 2
(out of 29 participants) (out of 9 participants)
Sudden kidney injury 3.4% (1) 0.0% (0)
Fever 3.4% (1) 0.0% (0)
Injection site reaction 3.4% (1) 0.0% (0)
Unexplained death 0.0% (0) 11.1% (1)
Serious adverse reactions related to durvalumab
There were 11 participants in Part 1 who did not get any durvalumab. So, the results
below are for 18 out of 29 participants in Part 1 and all 9 participants in Part 2.
Part 1 Part 2
(out of 18 participants) (out of 9 participants)
Sudden kidney injury 5.6% (1) 0.0% (0)
Diarrhea 5.6% (1) 0.0% (0)
In Part 1, none of the participants died because of serious adverse reactions.
In Part 2, 11.1% of the participants died because of serious adverse reactions
related to MEDI5083. This was 1 out of 9 participants. The serious adverse
reaction was unexplained death. None of the participants in Part 2 died because
of serious adverse reactions related to durvalumab.
9 | Clinical Study Results